Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

Alzheimer's disease (AD) is a major healthcare challenge with no curative treatment at
present. To address this challenge, we need a paradigm shift, where we focus on pre …

A large body of clinical and nonclinical evidence supports the role of neurotoxic soluble beta
amyloid (amyloid, Aβ) oligomers as upstream pathogenic drivers of Alzheimer's disease …

Importance The behavioral variant of Alzheimer disease (bvAD) is characterized by early
and predominant behavioral deficits caused by AD pathology. This AD phenotype is …

Purpose The development of blood biomarkers that reflect Alzheimer's disease (AD)
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …

Alzheimer's disease (AD) is the most common age-related progressive neurodegenerative
disease, characterized by a decline in cognitive function and neuronal loss, and is caused …

Damage or loss of brain cells and impaired neurochemistry, neurogenesis, and synaptic and
nonsynaptic plasticity of the brain lead to dementia in neurodegenerative diseases, such as …

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with
Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging …